✦ LIBER ✦

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Scribed by Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Van Assche; Zbigniew Hebzda; Leszek Paradowski; Geert D'Haens; Subrata Ghosh; Brian Feagan; Paul J. Rutgeerts; Gerard Dijkstra; Dirk J. De Jong; Bas Oldenburg; Mahdi Farhan; Yann Dean; Daniel W. Hommes

Book ID: 119428192
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 87 KB
Volume: 134
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(08)60317-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Efficacy and safety of itolizumab, a nov

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 694 KB

Efficacy and safety of secukinumab, a fu

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

✍ McInnes, I. B.; Sieper, J.; Braun, J.; Emery, P.; van der Heijde, D.; Isaacs, J. 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 471 KB

A Multicenter, Randomized, Double-Blind,

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

✍ William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Joha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 145 KB